• No results found

Prognosis in monoclonal proteinaemia Schaar, C.G.

N/A
N/A
Protected

Academic year: 2021

Share "Prognosis in monoclonal proteinaemia Schaar, C.G."

Copied!
7
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Citation

Schaar, C. G. (2006, November 9). Prognosis in monoclonal

proteinaemia. Retrieved from https://hdl.handle.net/1887/4983

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion ofdoctoral thesis in the Institutional Repository of the University of Leiden

(2)

Appendices

(3)
(4)

Acknowledgements

The studies presented in this thesis would not have been possible without the endeav-our and cooperation of many. First I would like to thank all co-authors for their con-tinued support, critical appraisal and friendship. It would be impossible to name all those that contributed but some deserve a special mentioning:

The population-based Paraprotein database was established at the Comprehensive Cancer Centre West (CCCW, Integraal Kankercentrum West) in cooperation with the physicians (especially clinical chemists) of the regional participating hospitals. The ‘Paraprotein Taskforce’ was chaired by my promoter Prof. Hanneke Kluin-Nelemans, whose never ending enthusiasm and working spirit inspired all (me !) to continue. The CCCW offered the backbone for the main project structure, organ-ized the meetings, the structure of the database and all the data management. Without this support, the project would not have been possible. Cisca Ong in particular admirably devised the initial database and Simone Snijder equally admirably contin-ued the follow-up of all initial participants. To both I want to say a heartfelt ‘thank you’. I was privileged to have been given the opportunity to work on this CCCW database.

Rob Bieger (Department of Internal Medicine, Bronovo Hospital, The Hague) not only taught me how to be an internist but also how to love this profession. In addi-tion he inspired me to start with on the Paraprotein Database. Prof. Roel Willemze (Departement of Hematology, Leiden University Medical Centre, Leiden) not only gave me the opportunity to become a haematologist but also facilitated my further work on this thesis.

The members of the Paraprotein Taskforce faithfully attended meetings and shared in the creation of all mentioned studies and resulting papers in addition to always critically appraising all found and presented data.

I thank Dr. Pierre Wijermans (Departement of Haematology, Haga Hospital, The Hague) especially for giving me an opportunity to look at the data on M-protein decrements in the HOVON-16 trial in addition of being able to report on the final data of this study. Data management on the HOVON-16 study was carried out by Chantal te Marvelde.

Dr. Paul Franck and especially Dr. Eric Vermeer (Department of Clinical Chemistry, Haga Hospital, The Hague) made it possible to analyse the serum syndecan data. Statistics form the backbone in these mostly epidemiological studies. Dr. Jo Hermans but especially Dr. Saskia le Cessie deserves a very special thank you. She has the uncanny capability of dealing very nicely with medical doctors inexperienced in both SPSS and statistics.

(5)

Stephan Kamphuis, clinical chemist at Gelre ziekenhuizen, I would like to thank for kindly providing Figures 5a, 5b and 6 in the Introduction.

Prof. Dr. Frits Rosendaal (Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden) I would like to thank for learning me how to critically inves-tigate the reported connection between solid tumours and monoclonal proteinaemia. I would like to thank Dr. Harald Schulze (Labor für Pädiatrische Molekularbiologie, Charité Hospital, Berlin, Germany) for his critical appraisal of the whole manuscript. All my colleagues from the Interne Maatschap and the outpatient polyclinic Internal Medicine at Gelre ziekenhuizen furthermore showed their continued warm support in giving me every opportunity to finally finish this thesis.

(6)

All members of the Paraprotein Task Force of the Comprehensive Cancer Centre West

Prof. Dr. J.C. Kluin-Nelemans (chairman, internist-haematologist) Dr. R. Bieger (internist-haematologist)

Dr. S. le Cessie (medical statistician) Dr. P.F.H. Franck (clinical chemist) Dr. W.B.J. Gerrits (internist-haematologist) Dr. J. Hermans (medical statistician) Dr. W. de Kieviet (clinical chemist) Prof. Dr. P.H.M. Kluin (pathologist) Dr. H. Kruijff (for the CCCW)

Prof. Dr. E.M. Noordijk (radiation-oncologist) Dr. F. Ong (radiation-oncologist)

Drs. C.G. Schaar (internist-haematologist) Drs. S. Snijder (datamanager)

Dr. P.W. Wijermans (internist-haematologist)

Hospitals in the region of the Comprehensive Cancer Centre West

Bronovo Hospital, The Hague Diaconessenhuis, Leiden Groene Hart Hospital, Gouda Haga Hospital, The Hague

– location Leyenburg

– location Rode Kruis Lange Land Hospital

– location Voorburg

– location Zoetermeer

Leiden University Medical Centre, Leiden Medical Centre Haaglanden

– location Antoniushove, Leidschendam

– location Westeinde, The Hague Reinier de Graaf Gasthuis, Delft Rijnland Hospital

– location St. Elisabeth, Leiderdorp

– location Rijnoord, Alphen aan de Rijn.

(7)

Referenties

GERELATEERDE DOCUMENTEN

’Solid Tumour Group’ versus ‘M-proteinaemia Only Group/MGUS’ To study whether patients with M-proteinaemia and a solid tumour (i.e. ‘Solid Tumour Group’) had

In a previous study, using our database that also included a large number of patients with multiple myeloma, we devised a Myeloma Risk Score using the M-protein serum level and

Therefore, the relation between survival and the rate of monoclonal protein (M-protein) decrement during the first cycles of therapy was prospectively assessed in 262 patients

Background: The effect of interferon- α 2b (IFN-α) on progression free and overall survival as well as quality of life was studied in mainly elderly patients with multiple myeloma

Not surprisingly, survival was also influenced by the M-protein related internal diagnosis especially MGUS associated with a solid tumour (median 0.4 (95% CI 0.2-0.5) years) compared

Serum IL-6 spiegels werden bepaald in 212 duidelijk omschreven patiënten met M- proteïnemie: multipel myeloom (60), andere hematologische ziekten (46), solide tumoren

Hierna was hij negen maanden werkzaam als arts-assistent niet in opleiding op de afdeling Interne Geneeskunde van het Bronovo Ziekenhuis te Den Haag, alwaar per 1 januari 1993

Serum interleukin-6 has no discriminatory role in para- proteinaemia nor a prognostic role in multiple myeloma.. Ong F, Hermans J, Noordijk EM, Schaar CG,